WallStSmart
ADIL

Adial Pharmaceuticals Inc

NASDAQ: ADIL · HEALTHCARE · BIOTECHNOLOGY

$1.44
-8.68% today

Updated 2026-06-05

Market cap
$5.25M
P/E ratio
P/S ratio
EPS (TTM)
$-4.89
Dividend yield
52W range
$1 – $19
Volume
0.1M

Adial Pharmaceuticals Inc (ADIL) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-209.05%
ROA
-110.90%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$0.00$-817993.00
2016$0.00$-420200.00
2017$0.00$-1.14M
2018$0.00$-11.63M
2019$0.00$-8.59M
2020$0.00$-10.86M
2021$0.00$-19.42M
2022$0.00$-12.73M
2023$0.00$-7.00M
2024$0.00$-13.20M
2025$0.00$-7.98M

Frequently asked questions

How much free cash flow does ADIL generate?

ADIL produced $-6.49M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ADIL's balance sheet healthy?

ADIL holds $5.88M in cash and equivalents against — in long-term debt, on $5.28M of shareholder equity. That debt is best read against the cash flow the business throws off each year.